LONDON (Thomson Financial) - GlaxoSmithKline PLC said biological activity was seen in 41 pct of patients in a phase II trial of pazopanib in patients with cancer of the ovaries, fallopian tube or peritoneum.
The trial evaluated patients who failed to respond to standard platinum-based therapy.
Pazopanib, like Roches top-selling Avastin, is an angiogenesis inhibitor, which stop new blood vessels from forming. This chokes a tumour's nutrient supply and inhibits its growth.
Analysts believe drugs of this type have huge market potential, and could work in a variety of tumours.
The company presented the data at the annual American Society of Clinical Oncology (ASCO) meeting today. amy.brown@thomson.com ab/dca COPYRIGHT Copyright AFX News Limited 2007. All rights reserved. The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
The trial evaluated patients who failed to respond to standard platinum-based therapy.
Pazopanib, like Roches top-selling Avastin, is an angiogenesis inhibitor, which stop new blood vessels from forming. This chokes a tumour's nutrient supply and inhibits its growth.
Analysts believe drugs of this type have huge market potential, and could work in a variety of tumours.
The company presented the data at the annual American Society of Clinical Oncology (ASCO) meeting today. amy.brown@thomson.com ab/dca COPYRIGHT Copyright AFX News Limited 2007. All rights reserved. The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.